Author

Takayo Matsumura

Observed name: T. Matsumura

Institution: Maruho (Japan)

Observed institutions: Kyoto University, Tokyo Women's Medical University, Maruho (Japan)

ORCID: 0000-0002-0986-8469

Observed ORCID: 0000-0002-0986-8469

OpenAlex ID: A5006984166

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

2020 · Kenji Kabashima, Takayo Matsumura, et al. · New England Journal of Medicine · 373

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies*

2021 · K. Kabashima, T. Matsumura, et al. · British Journal of Dermatology · 138

Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study

2023 · Atsuyuki Igarashi, Toshio Katsunuma, et al. · British Journal of Dermatology · 60

Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years

2024 · Hiroo Yokozeki, Hiroyuki Murota, et al. · British Journal of Dermatology · 22

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

2023 · Kenji Kabashima, Takayo Matsumura, et al. · Dermatology and Therapy · 14

Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study

2025 · Hiroo Yokozeki, Hiroyuki Murota, et al. · British Journal of Dermatology · 11

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

2023 · Kenji Kabashima, Takayo Matsumura, et al. · Journal of Dermatological Treatment · 11

Works count: 7

Citation count: 629

H-index: 7

I10-index: 7